Josh Arnold Investment Consultant LLC Takes $1.42 Million Position in Cellebrite DI Ltd. $CLBT

Key Points

• Josh Arnold Investment Consultant LLC has acquired 73,000 shares of Cellebrite DI Ltd. valued at approximately $1.4 million, making it the 9th largest position in their portfolio.
• Cellebrite DI's recent earnings report showed earnings per share of $0.12, exceeding analysts' expectations, with revenue up 18.4% compared to the previous year.
• Analysts have mixed ratings on Cellebrite DI, with a consensus target price of $22.40 and several adjusting their target prices downward in recent reports.

Josh Arnold Investment Consultant LLC acquired a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 73,000 shares of the company's stock, valued at approximately $1,418,000. Cellebrite DI accounts for approximately 1.2% of Josh Arnold Investment Consultant LLC's holdings, making the stock its 9th biggest holding.

Other institutional investors also recently made changes to their positions in the company. OneDigital Investment Advisors LLC lifted its holdings in Cellebrite DI by 2.5% in the 1st quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company's stock valued at $556,000 after purchasing an additional 688 shares in the last quarter. Bosun Asset Management LLC grew its position in Cellebrite DI by 2.5% in the first quarter. Bosun Asset Management LLC now owns 44,376 shares of the company's stock valued at $862,000 after acquiring an additional 1,069 shares in the last quarter. Advisors Asset Management Inc. grew its position in shares of Cellebrite DI by 24.7% during the first quarter. Advisors Asset Management Inc. now owns 6,133 shares of the company's stock worth $119,000 after buying an additional 1,214 shares in the last quarter. Assetmark Inc. acquired a new stake in shares of Cellebrite DI during the first quarter worth approximately $33,000. Finally, HighTower Advisors LLC lifted its stake in Cellebrite DI by 16.3% during the first quarter. HighTower Advisors LLC now owns 14,485 shares of the company's stock worth $281,000 after purchasing an additional 2,029 shares during the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on CLBT. Wall Street Zen raised Cellebrite DI from a "hold" rating to a "buy" rating in a report on Saturday, August 16th. JPMorgan Chase & Co. reduced their price target on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a report on Monday, May 12th. Needham & Company LLC reduced their target price on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, August 14th. Finally, Lake Street Capital reduced their price objective on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a research report on Friday, August 15th. Five research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Cellebrite DI presently has an average rating of "Buy" and an average target price of $22.40.

Cellebrite DI Stock Up 1.1%

Shares of CLBT traded up $0.18 during trading hours on Tuesday, hitting $17.27. 2,348,790 shares of the company were exchanged, compared to its average volume of 1,703,442. The firm's fifty day moving average is $15.05 and its 200 day moving average is $16.99. The company has a market cap of $4.14 billion, a price-to-earnings ratio of -22.72, a P/E/G ratio of 3.02 and a beta of 1.28. Cellebrite DI Ltd. has a fifty-two week low of $13.10 and a fifty-two week high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The firm had revenue of $113.28 million during the quarter, compared to the consensus estimate of $112.33 million. During the same period last year, the company earned $0.10 earnings per share. The business's quarterly revenue was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.